M-SRG
品系全名
SD-Rag2em1SmocIl2rgem1Smoc
目錄號
NR-KO-210360
品系狀態
活體
基因信息
基因名
品系描述
驗證數據
Fig1. Complete deletion of T, B and NK cells of M-SRG rats. Spleen and peripheral blood cells from SD and M-SRG rats were collected to analyze their compositions of T, B and NK cells by FACS.
Fig2. Subcutaneous xenograft tumor growth of HT29 cells in M-SRG rats. Human colorectal adenocarcinoma cell line HT-29 (2x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig3. Subcutaneous xenograft tumor growth of PC-3 cells in M-SRG rats. Human prostatic adenocarcinoma cell line PC-3 (2x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig4. Subcutaneous xenograft tumor growth of LNCaP clone FGC cells in M-SRG rats. Human metastatic prostate carcinoma cell line LNCaP clone FGC (2x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig5. Subcutaneous xenograft tumor growth of A2780 cells in M-SRG rats. Human ovarian cancer cell line HT-29 (1x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig6. Subcutaneous xenograft tumor growth of MV4-11 cells in M-SRG rats. Human monocytic leukemia cell line MV4-11 (1x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig7. Subcutaneous xenograft tumor growth of OCI-AML-3 cells in M-SRG rats. Human acute myeloid leukemia cell line OCI-AML-3 (1x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A) Tumor volume. (B) Body weight change.
Fig8. Blood Routine Tests in M-SRG rats.
Fig9. Blood biochemistry in M-SRG rats.
你也可能感興趣
Cre-ERT2在無Tamoxifen誘導的情況下,在細胞質內處於無活性狀態;當Tamoxifen誘導後,Tamoxifen的代謝產物4-OHT(雌激素類似物)與ERT結合,可使Cre-ERT2進核發揮Cre重組酶活性。
查看